Andrew Stasiak

Andrew Stasiak is an experienced executive in quality assurance, currently serving as the Executive Director of GxP Quality Assurance at Immedica Pharma AB since June 2022, where responsibilities include overseeing global quality systems and compliance. Prior to this role, Andrew held the position of Vice President of Quality at Medivant Healthcare from November 2016 to June 2022, leading the establishment of a sterile injectable manufacturing facility through to FDA inspection. Andrew also served as the Director of Quality Assurance at Insys Therapeutics, Inc. from August 2011 to November 2016, where a comprehensive Quality Management System was developed to align with GxP standards. Earlier in Andrew's career, a supervisory role in analytical quality control was held at Jubilant HollisterStier Contract Manufacturing & Services from November 2004 to August 2011. Andrew holds a Master of Science in Regulatory Affairs from San Diego State University and a Bachelor of Science in Molecular and Cellular Biology from the University of Arizona.